Quick answer
Inflammation of the pancreas, ranging from mild to life-threatening. GLP-1 RAs carry a labeled warning about pancreatitis risk; patients should stop the medication and seek care if severe abdominal pain develops.
Full definition
Pancreatitis is inflammation of the pancreas presenting with severe epigastric pain, often radiating to the back, with nausea and vomiting. Acute pancreatitis has been reported in patients taking GLP-1 receptor agonists, and the FDA labels include warnings instructing patients to discontinue the medication and seek care for persistent severe abdominal pain. Causal relationship remains debated — large-scale meta-analyses have not consistently demonstrated significantly elevated pancreatitis risk above background, though signals exist. History of pancreatitis is a relative caution; gallstone disease is a related risk factor.
Deep dive
Pancreatitis: complete reference
Pancreatitis is inflammation of the pancreas — acute (sudden onset) or chronic (long-standing). Acute pancreatitis presents with severe upper abdominal pain that may radiate to the back, often с nausea and vomiting. Causes include gallstones (most common), alcohol, hypertriglyceridemia, medications, and genetic factors. GLP-1 receptor agonists have a documented (uncommon) association с pancreatitis — pooled trial data show ~0.2-0.4% incidence over treatment duration, similar to placebo in many analyses but slightly elevated in some. FDA prescribing labels include pancreatitis warnings for all GLP-1s. Patients with history of pancreatitis (especially recurrent) are typically excluded from GLP-1 therapy due to elevated risk. Symptoms warranting immediate evaluation: severe persistent epigastric pain, nausea/vomiting unresolving с antiemetics, pain radiating to back. Lab workup: elevated lipase (most specific) + amylase. Imaging: abdominal CT or MRI.
- In practice
- Severe abdominal pain that radiates to the back + persistent vomiting on a GLP-1 = immediate ER evaluation. Pancreatitis is uncommon but serious.
- Clinical context
- Pancreatitis is a documented uncommon adverse event для all GLP-1s. Prior pancreatitis history is a relative contraindication.
Medications
Pancreatitis is most directly relevant to the following GLP-1 medications:
Related terms
- Gastroparesis — A condition of delayed stomach emptying without mechanical obstruction. GLP-1 medications can cause …
- Boxed Warning — The strongest FDA warning, displayed in a literal box on the drug label. All GLP-1 RAs carry a boxed…
Continue learning
GLP1Zoom glossary is educational reference. Definitions are summary interpretations of clinical sources and not a substitute for prescribing-information detail. Full disclaimer.
References
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)